Panelists discuss how uncomplicated urinary tract infections (UTIs) are typically managed with empiric short-course antibiotics based on local resistance patterns while identifying significant gaps in the outdated 2010 Infectious Diseases Society of America (IDSA) guidelines, including insufficient guidance on emerging resistance trends, limited recommendations for alternative therapies, inadequate consideration of patient-specific factors, absence of antimicrobial stewardship protocols, and minimal direction on prevention strategies for recurrent infections.
Video content above is prompted by the following:
Real-World Data Show Bevacizumab Benefits Only High-Risk Patients With Epithelial Ovarian Cancer
May 13th 2025In line with previous clinical trial findings, real-world data show that bevacizumab improves outcomes in patients with epithelial ovarian cancer and high-risk prognostic factors.
Read More
For Patients Who Cannot Wait, This Off-the-Shelf CAR NK Treatment for AML Leaves Healthy Cells Alone
May 12th 2025First part of a 2-part interview with Stephen Strickland, MD, MSCI, director of leukemia research for Sarah Cannon Research Institute. Strickland recently presented data from a phase 1 trial of SENTI-202, an investigational chimeric antigen receptor (CAR) natural killer (NK) cell therapy.
Read More